Healthcare Industry News: cardiopulmonary
News Release - March 1, 2012
Allegheny General Hospital Implants Region's First SynCardia Total Artificial HeartDoctors Estimate up to 10 Patients a Year at Allegheny Could Benefit From the Total Artificial Heart as a Bridge to Transplant
TUCSON, AZ--(Healthcare Sales & Marketing Network)- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that Allegheny General Hospital (AGH) performed its first implant of the SynCardia temporary Total Artificial Heart on Feb. 17.
"We are extremely proud to be the first cardiovascular team in Pittsburgh to offer this revolutionary technology to patients with advanced heart failure. AGH has a distinguished history of pioneering achievements in the treatment of complex cardiovascular diseases and the SynCardia Total Artificial Heart is another significant milestone in that legacy," said George J. Magovern, MD, Chair, Department of Thoracic and Cardiovascular Surgery at AGH and the West Penn Allegheny Health System (WPAHS).
The patient, 62, was first admitted to a local hospital suffering from an acute heart attack. Doctors attempted cardiopulmonary resuscitation for nearly an hour before placing him on extracorporeal membrane oxygenation (ECMO), which takes over the function of the heart and the lungs. He was then transferred to Allegheny General Hospital, where cardiologists observed him for 24 hours. Initially, doctors had hoped to wean him off ECMO, or implant a left ventricular assist device (LVAD), which supports only the left side of the heart. However, they ultimately identified him as a candidate for the Total Artificial Heart.
"There is a small segment of people who really don't do well with an LVAD alone, and we have learned we needed something better," said cardiothoracic surgeon Stephen Bailey, MD, who performed the implant of the Total Artificial Heart.
"The side that's not supported can often fail in about 20 percent of patients," said cardiologist Raymond Benza, MD. "These are people we were never able to help before. This opens up a brand new door for these people."
Doctors said they believe up to 10 patients a year at AGH could benefit from receiving the Total Artificial Heart.
"The Total Artificial Heart leads to recovery of end organ function in the most critically ill patients, allowing transplantation to be performed when the patient is more stable -- which ultimately helps facilitate better outcomes following transplantation," said Dr. Bailey.
Under the direction of Drs. Benza and Bailey, the heart transplantation program at AGH has achieved a success rate that exceeds the national average and boasts the highest one-year survival rate of any transplantation program in Pennsylvania over the past two years, according to the national Scientific Registry of Transplant Recipients. This year the hospital also was one of just three heart transplant programs in the country noted for better than expected patient outcomes.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart... read more
Source: SynCardia Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.